Aviana (AVAH) Q2 2023: Preferred Payer Mix Rises to 16%, Accelerating Margin Recovery Path
Aviana’s Q2 marked a decisive pivot toward preferred payer alignment, with preferred payer volumes climbing to 16% of total Private Duty Services (PDS) hours, up from 13% last quarter, driving sequential EBITDA improvement and setting up further gains as new rate increases take effect in the back half. The company’s disciplined focus on rate negotiations, margin management, and payer mix is reshaping its earnings trajectory, even as labor and reimbursement headwinds persist. With a conservative guidance raise and clear levers for additional upside, Aviana’s execution on payer strategy and cost discipline will be the critical watchpoints into 2024.
Summary
- Payer Mix Shift: Preferred payer volumes reached 16%, unlocking higher reimbursement and margin leverage.
- Cost Control Momentum: Sequential EBITDA and margin improvement signal early benefits from rate hikes and expense actions.
- Guidance Upside Potential: Full-year outlook raised, with further upside tied to ongoing rate wins and payer mix optimization.
Business Overview
Aviana is a diversified provider of home and community-based healthcare services, primarily generating revenue through three core segments: Private Duty Services (PDS), which delivers non-clinical and skilled nursing care in the home; Home Health and Hospice, focused on episodic care and end-of-life services; and Medical Solutions (MS), offering medical supplies and ancillary services. The company’s business model is anchored in reimbursement from government payers, managed care organizations (MCOs), and commercial insurers, with a growing emphasis on aligning labor capacity with payers who provide higher rates and value-based incentives.
Performance Analysis
Aviana posted 6.5% year-over-year revenue growth, with sequential improvement in both revenue and adjusted EBITDA, reflecting initial benefits from payer rate negotiations and disciplined cost management. The PDS segment, which accounts for the majority of revenue, grew 8.5% year over year, driven by a 2.7% increase in care hours and a 5.8% increase in revenue per hour, despite continued labor constraints. The Medical Solutions segment delivered robust 15.9% growth, while Home Health and Hospice revenue declined 9.7% as the company actively shifted focus to higher-margin, episodic payers.
Gross margin for the quarter was essentially flat year over year but improved sequentially, with notable margin expansion in Home Health and Hospice as episodic admissions neared 70% of total. Cost of revenue per hour in PDS rose 5.2% year over year, reflecting labor market inflation, but sequential improvement in cost rates and spread per hour (up 7.3% YoY) point to early traction in wage pass-through and rate capture. Free cash flow remained negative, but management expects a return to positive cash generation by year-end as rate increases and volume growth materialize.
- PDS Volume Recovery: 2.7% YoY growth in PDS care hours marks a return to positive trajectory after pandemic-driven stagnation.
- Margin Expansion in Home Health: Gross margin climbed to 48.6% (from 44.6% in Q1) as the business shifts away from low-margin payers.
- Medical Solutions Outperformance: MS revenue and margin growth outpaced other segments, benefiting from provider exits and payer partnerships.
Overall, Aviana’s results reflect a business in transition, with payer mix, rate negotiation, and cost control as the primary levers for margin and volume growth through 2023 and into 2024.
Executive Commentary
"Our ability to recruit and retain the best talent is a function of rate. Our business model offers a preferred work setting that is mission-driven, providing a deep sense of purpose for our teammates. However, our caregivers need to be able to provide for themselves and their families in this inflationary environment, and we must offer a competitive wage."
Jeff Shainer, Chief Executive Officer
"Preferred payers reimburse us a fair rate and we pay market competitive wage rates while also earning value-based payments for achieving positive clinical outcomes and improved staff hours. We are encouraged by our 2023 rate increases and the subsequent recruiting results and believe our business can rebound quickly as we achieve our rate goals previously discussed."
Jeff Shainer, Chief Executive Officer
Strategic Positioning
1. Accelerating Preferred Payer Strategy
Aviana’s pivot to preferred payers—those offering higher reimbursement rates and value-based incentives—has become the central strategic lever. The company increased its preferred payer mix in PDS from 13% to 16% in Q2 and targets 20% by year-end, with Texas already above 50%. This mix shift enables higher wage pass-throughs to caregivers and supports volume growth, while also improving admission rates and clinical outcomes.
2. Legislative and Rate Advocacy
Securing double-digit rate increases in six key states and additional wins across 11 others (covering 50% of the PDS footprint) demonstrates effective advocacy, though major states like California remain pending. Most rate increases are back-half loaded, setting up a stronger 2024, but the timing and magnitude of wins in large states will be critical for long-term margin expansion.
3. Cost Structure and Margin Focus
Management is aggressively right-sizing corporate overhead and optimizing collections, with cost initiatives already visible in sequential gross margin and EBITDA improvement. The company is also leveraging technology and operational discipline to support scalable growth, particularly in Medical Solutions and Home Health as low-margin contracts are culled.
4. Liquidity and Capital Structure Management
Aviana extended its AR securitization facility for three years, maintaining $175 million in liquidity, and holds $205 million in total liquidity at quarter’s end. With hedges in place on nearly all variable-rate debt and no significant maturities until 2028, the balance sheet provides operational flexibility as the company navigates rate and labor transitions.
Key Considerations
Aviana’s Q2 results reflect a business in active transformation, with payer mix, rate advocacy, and labor alignment at the center of its strategy. Investors should weigh the following:
Key Considerations:
- Payer Concentration Risk: Success hinges on expanding preferred payer contracts, particularly in large states like Texas and California, which can materially swing margin outcomes.
- Labor Availability as a Growth Governor: Volume growth is constrained by caregiver supply, with wage competitiveness tied directly to reimbursement rate success.
- Seasonality and Timing of Rate Increases: Q3 is expected to be seasonally soft, with most rate and volume benefits concentrated in Q4 and beyond.
- Margin Normalization in PDS: Spread per hour benefited from timing items in Q2 and is expected to normalize in the $10–$10.50 range in the back half, impacting margin trajectory.
- Cash Flow Inflection: Return to positive operating and free cash flow is forecast for Q4, contingent on execution of rate and volume plans.
Risks
Execution risk remains elevated as Aviana depends on ongoing legislative wins and payer negotiations to sustain margin and growth improvements. Delayed or smaller-than-expected rate increases in California and other large states could materially impact 2024 earnings. Labor market tightness continues to cap growth, and failure to align wage rates with inflation could limit recruitment and retention, stalling volume recovery. Reimbursement and regulatory volatility in government-funded healthcare also presents ongoing uncertainty.
Forward Outlook
For Q3, Aviana guided to:
- Seasonally flat or slightly lower revenue and EBITDA, reflecting typical summer volume softness and timing of rate increases.
- Q3 expected to contribute 25–26% of full-year adjusted EBITDA, with a ramp in Q4 as cost savings and rate actions take fuller effect.
For full-year 2023, management raised guidance:
- Revenue of $1.85 billion to $1.86 billion
- Adjusted EBITDA of $132 million to $135 million
Management highlighted several factors that will shape results in the back half:
- Majority of rate increases take effect July through October, setting up a Q4 earnings lift
- Preferred payer mix targeted to reach 20% by year-end, with further upside if additional contracts close
Takeaways
Aviana’s Q2 confirms that payer mix and rate advocacy are unlocking sequential margin gains and setting the stage for a stronger exit rate into 2024.
- Payer Mix as Margin Driver: Each percentage point shift to preferred payers brings higher reimbursement, wage competitiveness, and clinical alignment, directly impacting margin and volume potential.
- Cost Initiatives Taking Hold: Sequential margin and EBITDA improvement are early signals that cost discipline can offset some labor inflation and reimbursement lag.
- 2024 Hinges on California and Labor Supply: The timing and scale of California rate increases, alongside continued labor recruitment, will determine whether Aviana can sustain and accelerate its current recovery momentum.
Conclusion
Aviana’s strategic execution on payer alignment, rate advocacy, and cost control is beginning to reshape its margin profile and earnings power. The next two quarters will be pivotal, as the full impact of legislative wins and preferred payer expansion becomes visible in both volume and margin, setting the tone for 2024 and beyond.
Industry Read-Through
Aviana’s experience underscores a broader trend in home-based healthcare: providers are increasingly prioritizing payer mix and rate negotiation over pure volume growth, as labor constraints and inflationary pressures persist. The company’s ability to secure double-digit rate increases in multiple states and expand value-based payer partnerships highlights a shift toward value-based care models and the importance of aligning with payers who recognize the cost savings of home care versus acute settings. Competitors and adjacent providers should expect continued margin bifurcation between those able to negotiate higher rates and those dependent on legacy, low-margin contracts. The sector’s recovery and growth will likely track the pace of labor market normalization and the success of advocacy efforts at the state level, particularly in large, slow-moving markets like California.